Officer and Employee Incentives Through the Issuance of Paid Stock Options
First written in FY2017-Q1. 6 of 9 entries say "Advanced", first in FY2018. Latest entry: FY2026-H1.
- FY2026-H1AdvancedAnnual report
「Series 15 Stock Acquisition Rights Categories and number of grantees (people) External collaborators 1 Number of stock acquisition rights (rights)* 200 (Note 1) Class, description and number of shares underlying the stock acquisition rights (shares)* 20,000 common shares (Note 1) Exercise period for the stock acquisition rights* From 1 December 2029 to 31 July 2035」
The Company issued Series 15 stock acquisition rights representing 20,000 shares, consisting of 200 rights, to 1 external collaborator, with an exercise period from December 2029 through July 2035. - FY2025AdvancedAnnual report
「Series 16 Stock Acquisition Rights Number of stock acquisition rights (rights)* 850 (Note 1) Class, description and number of shares underlying the stock acquisition rights (shares)* 85,000 common shares (Note 1) Exercise period for the stock acquisition rights* From 1 December 2029 to 31 July 2035」
The Series 16 stock acquisition rights representing 85,000 shares were granted on 19 September 2025 to executive officers and employees of a wholly owned subsidiary, with an exercise period from December 2029 through July 2035. - FY2024-Q1AdvancedAnnual report
「Series 13 Stock Acquisition Rights Number of stock acquisition rights (rights)* 6,180 (Note 1) Class, description and number of shares underlying the stock acquisition rights (shares)* 618,000 common shares (Note 1) Exercise period for the stock acquisition rights* From 1 January 2027 to 30 November 2031 Series 14 Stock Acquisition Rights Number of stock acquisition rights (rights)* 530 (Note 1) Class, description and number of shares underlying the stock acquisition rights (shares)* 53,000 common shares (Note 1) Exercise period for the stock acquisition rights* From 1 January 2027 to 30 November 2032」
The Series 13 and Series 14 stock acquisition rights approved on 1 December 2023 were issued to directors, executive officers, employees and others, representing a total of 671,000 shares, with exercise periods beginning in 2027. - FY2021AdvancedAnnual report
「Company employees 1 Number of stock acquisition rights (rights)* 250 (Note 1) Class, description and number of shares underlying the stock acquisition rights (shares)* 25,000 common shares (Note 1) Exercise period for the stock acquisition rights* From 1 January 2024 to 24 December 2028」
Under the Series 12 stock acquisition rights approved in June 2021, 25,000 shares were granted to 1 employee, with an exercise period established from 2024 through 2028. - FY2021-Q1AdvancedAnnual report
「Resolution date 17 November 2020 Categories and number of grantees (people) Company directors 3 people, 4,800 rights Company employees 12 people, 3,710 rights Employees of Company subsidiaries 9 people, 610 rights Number of stock acquisition rights (rights)* 9,120 rights (Note 1) Class and number of shares underlying the stock acquisition rights (shares)* 912,000 common shares (Note 1) Exercise period for the stock acquisition rights* From 1 January 2024 to 24 December 2028」
The Company issued 9,120 new stock options representing 912,000 shares to directors and employees of the Company and its subsidiaries, and established an exercise period from 2024 through 2028. - FY2020Forfeiture and cancellation of unvested portionAnnual report
「Before vesting (shares) End of previous consolidated fiscal year 630,000 Granted - Forfeited and cancelled 450,000 Vested - Unvested balance 180,000 After vesting (shares) End of previous consolidated fiscal year 70,000 Vested - Exercised - Forfeited and cancelled - Unexercised balance 70,000」
Of the Series 7 paid stock options, 450,000 unvested shares were forfeited and cancelled, leaving an unvested balance of 180,000 shares. The vested but unexercised balance was 70,000 shares. - FY2018AdvancedAnnual report
「Before vesting (shares) End of previous consolidated fiscal year 700,000 Granted — Forfeited — Vested 70,000 Unvested balance 630,000」
Of the performance-based Series 7 stock acquisition rights, 70,000 shares vested, leaving an unvested balance of 630,000 shares. - FY2017-Q2RestatedAnnual report
「Number of stock acquisition rights 7,000 Class and number of shares underlying the stock acquisition rights 700,000 common shares of the Company Exercise price of the stock acquisition rights ¥3,275 per share Exercise period for the stock acquisition rights From 1 January 2018 to 31 March 2025」
The number, exercise price and exercise period of the paid stock options for officers and employees continued to be disclosed without change from the previous quarter. - FY2017-Q1First statedAnnual report
「At a Board of Directors meeting held on 16 January 2017, the Company resolved, pursuant to Articles 236, 238 and 240 of the Companies Act, to issue stock acquisition rights to the Company’s directors and employees and the directors and employees of its subsidiaries, as set out below. Payment was completed by 31 January 2017. Number of stock acquisition rights 7,000 Class and number of shares underlying the stock acquisition rights 700,000 common shares of the Company Exercise price of the stock acquisition rights ¥3,275 per share Exercise period for the stock acquisition rights From 1 January 2018 to 31 March 2025」
The Company issued 7,000 paid stock acquisition rights representing 700,000 shares to directors and employees of the Company and its subsidiaries, and established an exercise period and performance conditions.